Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...

Members of the NIH’s recently reconstituted scientific management review board had strong reactions to congressional ...

Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Gene therapy that alters hemoglobin genes may be an answer to curing sickle cell disease (SCD) and beta thalassemia. When the normal DNA sequence in an individual changes or mutates it can cause ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

This test will provide interpretations for sickle cell disease (SCD) and beta thalassemia in the field. The Gazelle™ Ferritin FIA Test will offer highly accurate measurement of ferritin levels for ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.43, a high estimate of $10.00, ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...